PATENT CLAIM ANALYSIS

Application Number: 16088397
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["544", "343000"]

Abstract:
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Claim (Index 18):
The method according to  claim 15 , wherein the one or more other therapeutic agents are anti-depressive agents selected from one or more of amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelazine sulfate, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 97.0
- Lexical Diversity: 1.30769
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14394467', '15629481', '14627968', '14777466', '16056143']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7991417037025262
- 35 USC 102 Novelty (BERT): 0.5446097129027735
- Combined Prediction Score: 0.773688504622551
- Mean Citation Score: 383.6470800000001
- Max Citation Score: 401.85004
- Similarity Product: 256.64629455797194

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test